Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20335)	5/10/1998 11:24:00 PM
From: Harrison Hickman	Read Replies (4) \| Respond to of 32384

<<Services such as Zack's converts the rating of each brokerage firm into one of the five numbers. . . . Ligand will have three STRONG BUYS (Bear Stearns, Lehman Brothers, and Legg Mason) and two BUYS (Hambrecht & Quist and Robertson Stephens). Zacks also gives their own rating which is based on upcoming earnings. Last time I looked, Zacks gave LGND a BUY, which is rather high for Biotechs. . . . As most readers of this board know, Biotechs, in general, are risky and are not for everyone. . . . Of course, the three most recent reports on LGND indicate that they will make money next year, which certainly could change LGND's risk rating. . . . LGND's EPS growth has been projected in the 50% to 100% which of course would translate into $48 to $84 price, which I'm sure would make most LGND investors extremely happy next year.>> Henry, What has been the track record of Zack's ratings of LGND and LGND's stock performance to this point? Harrison Hickman